Rethinking Precision Medicine: From Mutations to Molecular Pathways

In this episode of The Promise of Personalized Medicine, Perry sits down with Aditya Pai, a genetic counselor by training and a leader at Genialis, where he works at the intersection of biology-driven analytics, AI, and oncology drug development.Aditya brings a practitioner’s and innovator’s perspective to what personalized medicine truly means today—moving beyond one-size-fits-all care and even beyond single-gene mutations, toward a more holistic understanding of disease biology. Together, they explore how RNA-based insights, pathway-level analysis, and machine learning are reshaping how cancers are understood, treated, and studied across the drug development lifecycle.Aditya shares insights about:Why personalized medicine is not new—but how advances in AI, transcriptomics, and systems biology are making it more actionable than everHow biology-driven, pathway-level approaches outperform single-mutation thinking in complex diseases like cancerThe role of AI and machine learning in building “foundation models” for cancer that help explain response, resistance, and relapseUsing therapeutic intelligence to improve drug discovery, clinical trial design, patient stratification, and combination therapy decisionsHow diagnostics are increasingly guiding therapeutics, and why elevating the value of diagnostic insights is critical to accelerating adoptionThe continued importance of clinical guidelines—and how they can coexist with truly individualized careReal-world examples where understanding underlying biology unlocked better outcomes, even when mutations alone fell shortThis episode offers a thoughtful, forward-looking look at how personalized medicine is evolving—from clinical care to population-level insights—and what it will take to translate cutting-edge science into meaningful, ethical, and accessible outcomes for patients.—-------Stay connected with our host, Perry Dimas, here on LinkedIn! 📧 Interested in joining our medical director advisory group? Email us at [email protected] 🔗 Connect on LinkedIn: linkedin.com/company/accessdx